Xeris Pharma's low blood sugar treatment wins FDA approval

The U.S. Food and Drug Administration has approved Xeris Pharmaceuticals Inc's glucagon pen that aims to treat severely low sugar levels in diabetes patients, the drugmaker said on Tuesday. The condition, called hypoglycemia, can cause acute cognitive impairment. It can occur multiple times a month, can also result in heart disease, seizure and coma in its severe form. Gvoke, Xeris' glucagon pen is an pre-filled device with liquid stable form of glucagon.

Upload Company Info



Chemxpert Demo Video


Dataset Sample


Chemical Name

Synonyms

Molecular Formula

Molecular Weight


To Access this information please pay by using "Pay & Download" button.

Pay & Download

Dataset Sample


Product Name Innovator

To Access this information please pay by using "Pay & Download" button.

Pay & Download

Dataset Sample


Product Name Market Status

To Access this information please pay by using "Pay & Download" button.

Pay & Download

Dataset Sample


Product Name Indication

To Access this information please pay by using "Pay & Download" button.

Pay & Download

Dataset Sample


Product Name Therapeutic Segment

To Access this information please pay by using "Pay & Download" button.

Pay & Download

To Access this information please pay by using "Pay & Download" button.

Pay & Download

Thank you for your enquiry

Your product will be updated soon in our database


Submit Your Query



Select Any Option



Page loaded in 0.001219 seconds